Oculus Innovative Sciences Reports Revenues of $3.3 Million for Third Quarter of Fiscal 2014 Feb 13, 2014
Oculus Innovative Sciences Announces Completion of Agreements Required for IPO by Company's Subsidiary, Ruthigen, Inc. Feb 6, 2014
Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn(R) in the Topical Treatment of Mild to Moderate Acne Feb 4, 2014
Oculus Innovative Sciences Announces Fiscal Third Quarter 2014 Financial Results and Conference Call Jan 30, 2014
Oculus Innovative Sciences Introduces Two New Microcyn(R) Advanced Wound Care Products for U.S. Prescription Wound Care Market Jan 7, 2014
Oculus Innovative Sciences Receives Notification of Compliance With the Stockholders' Requirement of the NASDAQ Listing Rules Dec 30, 2013
Oculus Innovative Sciences Pays Off Debt to Strengthen Balance Sheet; Obtains $4.5 Million in Stockholders' Equity on a Pro Forma Basis as of September 30, 2013, Sufficient to Regain Compliance with NASDAQ Listing Rules Dec 19, 2013
Oculus Innovative Sciences Receives Mexican Ministry of Health Approval of Microcyn(R)-Based Hydrogel for Management of Scars Dec 12, 2013
Oculus Innovative Sciences Receives FDA Clearance for Microcyn(R) Scar Management HydroGel Dec 4, 2013
